CompletedPhase 2ketamine
Safety and Efficacy of Intranasal Ketamine for the Treatment of Postoperative Dental Pain
Sponsored by Javelin Pharmaceuticals
NCT ID
NCT00488787
Target Enrollment
40 participants
Start Date
2001-03
Est. Completion
2001-04
About This Study
Once patients' postoperative pain intensity reaches a moderate-to-severe level, they are randomized to receive intranasal ketamine or placebo. Patients remain in the study unit for 3 hours post administration and assess pain intensity and pain relief throughout the 3 hour postoperative period.
Conditions Studied
Interventions
- •intranasal ketamine
- •intranasal ketamine
- •intranasal ketamine
- •placebo
Eligibility
Age:16 Years - N/A
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Healthy patients at least 16 years of age requiring two or more third molar extractions Exclusion Criteria: * Less than 16 years old * Other exclusion criteria may apply